GSK plc (GSK) said on Monday that its application for extending the use of its respiratory syncytial virus (RSV) vaccine ...

Sotatercept-csrk was first approved in 2024 to treat pulmonary arterial hypertension (PAH) in adults based on results seen in the phase 3 STELLAR trial.

Veterans Affairs data-based study finds that changing from MDI to DPI is linked to greater healthcare use, though the veteran ...

PORTLAND, IN, UNITED STATES, July 14, 2025 /EINPresswire.com/ -- According to the report published by Allied Market Research, the global intelligent asthma monitoring devices market generated $180.5 ...

The Lancet on the anti-IL-5 antibody mepolizumab in individuals with allergic asthma, evidence has accumulated that the pathogenetic role of eosinophils is fundamentally different between asthma ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

The Business Research Company's Asthma and COPD Drugs Market 2025: Strategic Insights for Growth, Expansion, and Gaining Competitive Edge It will grow to $50.99 billion in 2029 at a compound annual ...

Asthma treatment in the UK has until recently relied heavily on a strategy of regular ‘maintenance’ inhaled corticosteroid (ICS) and separate ‘reliever’ inhalers containing short-acting beta-agonist ...

Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being ...

U.S. Senator Maggie Hassan (D-NH) is intensifying her scrutiny of GSK Plc (NYSE:GSK) over the company's decision to pull its ...

Amid ongoing controversy, Sen. Maggie Hassan (D-N.H.) is investigating GSK for replacing a popular asthma inhaler with a ...

Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...